Curis, Inc. (CRIS) Given Consensus Rating of “Buy” by Analysts
Curis, Inc. (NASDAQ:CRIS) has received a consensus recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $6.67.
A number of equities research analysts have recently issued reports on CRIS shares. Cowen and Company restated a “buy” rating on shares of Curis in a report on Wednesday, March 22nd. Zacks Investment Research cut Curis from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Finally, ValuEngine upgraded Curis from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd.
In other news, Director James R. Mcnab sold 76,276 shares of Curis stock in a transaction that occurred on Friday, May 5th. The shares were sold at an average price of $2.04, for a total value of $155,603.04. Following the completion of the sale, the director now directly owns 879,688 shares in the company, valued at $1,794,563.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director James R. Mcnab sold 146,694 shares of Curis stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $2.61, for a total transaction of $382,871.34. Following the completion of the sale, the director now owns 912,426 shares of the company’s stock, valued at $2,381,431.86. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 450,000 shares of company stock valued at $1,101,973. Corporate insiders own 4.07% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. State Street Corp increased its stake in Curis by 5.5% in the fourth quarter. State Street Corp now owns 1,663,980 shares of the biotechnology company’s stock worth $5,125,000 after buying an additional 86,308 shares during the last quarter. Two Sigma Investments LP acquired a new stake in Curis during the fourth quarter worth $183,000. Perceptive Advisors LLC acquired a new stake in Curis during the first quarter worth $1,390,000. Janney Montgomery Scott LLC increased its stake in Curis by 11.1% in the first quarter. Janney Montgomery Scott LLC now owns 123,644 shares of the biotechnology company’s stock worth $344,000 after buying an additional 12,344 shares during the last quarter. Finally, Teachers Advisors LLC increased its stake in Curis by 62.5% in the fourth quarter. Teachers Advisors LLC now owns 368,278 shares of the biotechnology company’s stock worth $1,134,000 after buying an additional 141,712 shares during the last quarter. Institutional investors own 51.63% of the company’s stock.
Curis (NASDAQ:CRIS) traded down 3.74% during trading on Tuesday, reaching $2.06. The company’s stock had a trading volume of 60,762 shares. The firm’s 50-day moving average is $1.82 and its 200-day moving average is $2.50. The stock’s market cap is $296.17 million. Curis has a 52-week low of $1.56 and a 52-week high of $3.72.
Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.02. Curis had a negative return on equity of 163.29% and a negative net margin of 841.05%. The business had revenue of $2.13 million for the quarter, compared to the consensus estimate of $1.98 million. During the same quarter in the previous year, the business posted ($0.07) EPS. The company’s revenue for the quarter was up 23.1% on a year-over-year basis. Equities research analysts forecast that Curis will post ($0.40) EPS for the current year.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.